Amryt Pharma Plc’s Combined Revenue Increases By 19.7% In 9M2019

  • Nov 05, 2019 GMT
  • Team Kalkine
  • Amryt Pharma Plc (AMYT) has released a trading update for the nine months ended 30 September 2019.
  • The combined company revenues increased by 19.7 per cent to $113.1 million, compared with $94.5 million for the same period in 2018 representing a growth rate of 19.7%
  • $51.1 million of revenue was generated through Juxtapid®/ Lojuxta® compared with $48.0 million for the same period in 2018, representing a growth rate of 6.5 per cent.
  • On 5th November 2019, at the time of writing, GMT 08:23 AM, AMYT shares were trading at GBX 121.50, up by 1.50 points or 1.25 per cent against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK